Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2a randomized double-blind placebo-controlled study of AGMB-129 in fibrostenotic Crohn’s disease
2022-502789-26-01Phase 2Completed
- Sponsor
- Agomab Therapeutics
- Start
- Oct 2023
- Modality
- Small Molecules
- Countries
- 8
01
Overview
Phase 2, randomised, double-blind trial in Crohn's disease comparing AGMB-129 with Placebo (2 arms). Primary endpoints: Adverse events, Clinical laboratory tests and 4 more. Started Oct 2023; status: completed.
02
Drugs
ontunisertib
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on 2022-502789-26-01.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-502789-26-01.